Posted July 19, 2019
The Food and Drug Administration (FDA) recently approved a gene therapy drug for a form of spinal muscular atrophy (SMA). Novartis is pricing the drug, Zolgensma, at $2.125 million, or $425,000 per year for five years. Read more.